Fig. 4: Antibody levels against SARS-CoV-2 nucleocapsid and spike proteins in patients receiving prior or ongoing Rituximab treatment. | Blood Cancer Journal

Fig. 4: Antibody levels against SARS-CoV-2 nucleocapsid and spike proteins in patients receiving prior or ongoing Rituximab treatment.

From: Production and persistence of specific antibodies in COVID-19 patients with hematologic malignancies: role of rituximab

Fig. 4

Antibody levels against SARS-CoV-2 nucleocapsid (N-Ab) and spike protein (S-Ab) were determined in hematological patients receiving prior or ongoing Rituximab treatment. Comparison of antibody levels in these two groups was determined at 1 (M1), 3 (M3), and 6 (M6) months after nasal swabs became PCR-negative. Statistically significant differences in antibody levels among the sample group were determined by a Student’s t test.

Back to article page